* Bio-Technology General Corp. (BTG), of Iselin, N.J., entered development and licensing agreements with Swiss Serum and Vaccine Institute Berne, in Berne, Switzerland, for BTG's third-generation recombinant hepatitis B vaccine in Western Europe, most of Latin America and various other countries. Swiss Serum will purchase the vaccine from BTG for distribution and provide milestone payments as well as royalties. The agreements cover the scaling-up of the manufacturing process, along with the clinical development, registration and marketing of the vaccine in licensed territory.
* CytRx Corp., of Atlanta, executed an asset purchase agreement with Oread Inc., of Lawrence, Kan., for divestiture of CytRx's wholly owned subsidiary, Proceutics Inc. Under the agreement, Proceutics will transfer its personnel, equipment and client contracts to Oread. Proceutics will retain its real estate assets, which it is negotiating to sell to an undisclosed purchaser, and Oread will execute a long-term lease for space in the Proceutics building. The transactions are expected to close before the end of February.
* Genetronics Biomedical Ltd., of Toronto, filed with the Securities and Exchange Commission to register securities. At the same time, the company applied to the Vancouver Stock Exchange for voluntary delisting. Genetronics is focused on electroporation, which uses electric fields to open cells and allow more efficient entrance of injected drugs. Since listing on the Vancouver exchange last September, the company noted a significant decrease in trading.
* NanoSystems LLC, of King of Prussia, Pa., entered a development, license and supply agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany. NanoSystems will apply its NanoCrystal technology to an undisclosed compound for respiratory delivery, and will receive an up-front license fee, milestone payments and royalties on net sales. NanoCrystal, used with poorly water-soluble drugs, formulates their active ingredients into nanometer-sized particles that can be incorporated into traditional dosage forms, including oral, injectable and aerosol products.
* NeuroVir, of Vancouver, British Columbia, entered a collaboration with Cephalon Inc., of West Chester, Pa., for the creation of models of Huntington's disease for evaluating new therapies. Cephalon will provide research funding and milestone payments to NeuroVir, which is focused on developing cancer and gene therapy products. Under certain conditions, Cephalon may make an equity investment in NeuroVir at a premium to the market value of the latter company's shares.
* PharmaPrint Inc., of Irvine, Calif., sold 2.25 million shares of common stock at $10.50 per share. CIBC Oppenheimer Corp., of New York, acted as underwriter, and has 30 days to exercise an overallotment option of 337,500 shares. PharmaPrint develops dietary supplements from plant extracts.